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Abstract
Type 2-immunity represents the typical adaptive response to allergen exposure in atopic individuals. It mainly
involves Th2 cells and immunoglobulin E, as the main orchestrators of type 2-inflammation. Recently, it has been
highlighted that allergens may be responsible for a Th2 response beside specific IgE activation and that a number
of other environmental stimuli, such as viruses and pollutants, can trigger the same pattern of inflammation beyond
atopy. Emerging data sustain a substantial role of the so-called epithelial dysfunction in asthma pathogenesis, both from
anatomic and functional point of view. Furthermore an increasing amount of evidence demonstrates the relevance of
innate immunity in polarizing a Th2 impaired response in asthmatic patients. Under this perspective, the complex cross-
talking between airway epithelium, innate and adaptive immunity is emerging as a major determinant of type
2-inflammation beyond allergens.
This review will include an update on the relevance of dysregulation of innate and adaptive type 2-immunity
in asthma pathogenesis, particularly severe asthma, and on the role of the allergens that are associated with
severe asthma. Type 2-immunity also will be reviewed in the light of the current and upcoming targeted
treatments for severe asthma.
Keywords: Innate immunity, Adaptive immunity, Type 2 inflammation, Asthma, Severe asthma, Allergic
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Key points
– Asthma pathogenesis can be explained as the
consequence of an epithelial barrier dysfunction,
which entails loss of anatomic integrity and
impaired functional, mainly immunological,
competence, the last aspect being strictly connected
with innate immunity.
– In atopic individuals allergen exposure promotes the
activation of Th2 cytokines, particularly IL-4, IL-5,
IL-9, and IL-13, which orchestrate and amplify type-
2 response.
– Eosinophil activation is the key-step of type 2-
inflammatory cascade, not only, but mostly in the
late allergic response, and eosinophils exert a central
role in asthma pathogenesis through the release of
four main proteins and a number of mediators
which sustain amplification of allergic response and
remodelling.
– Sensitization to several specific allergens, including
house dust mite (HDM), fungi, pollen, animal
dander and cockroach, are associated with a more
severe phenotype of allergic asthma.
– A number of allergens, including HDM and moulds,
are able to trigger a type 2 immune response in the
absence of specific IgE antibodies, by activating
airway epithelial Cells (AECs) via pathogen
recognition receptor (PAR) and toll-like receptors
(TLR) to produce TSLP, IL-25 and IL-33. The same
pattern can be activated by allergens proteases and
oxidative damage.
– Mainly in response to selective TLR (TLR 4, 5 and 9
particularly) stimulation and to injury operated by
environmental stimuli (viruses and pollutants), the
epithelial cells produce master regulatory cytokines,
including thymic stromal lymphopoietin (TSLP), IL-
25 and IL-33, which stimulate Th2 cells and type 2
innate lymphoid cells (ILC2) to produce Th2
cytokines.
– ILC2 orchestrate a second-line adaptive type 2 im-
mune response, a chronic eosinophilic airways in-
flammation in patients with asthma, particularly
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severe asthma, and an altered tissue repair processes
responsible for airway remodelling, which further
sustains the epithelial physical inefficiency.
– In the light of the emerging pathogenic role of
epithelial dysfunction and innate immunity, even
type 2-inflammation should be no more considered
as a consequence of allergenic stimuli only, but the
result of a complex cross-talking between airway
epithelium, innate and adaptive immunity.
– Th2 immunity actors represent the selective target
of a number of current and upcoming biological
treatments. Innate immunity, particularly TSLP, is
under investigation as a novel target for innovative
drugs.
Background: type 2 immune response
Traditionally, type 2-immunity is triggered by allergens
or parasitic infection and characterized by the differenti-
ation of naïve T CD4+ cells towards Th2 effector cells,
which is typically associated with IgE production, eo-
sinophilia and mast cell activation. The keystone cyto-
kines in type 2 immune response include interleukin
(IL) 4, IL-5, IL-9, and IL-13 [1, 2]. IL-4 is crucial for the
differentiation of naïve Th0 cells to Th2 cells, which in
turn induce isotype switching to IgE production. Specific
IgE antibodies bind to their high affinity receptors FceRI
on the surface of basophils or mast cells, leading to the
sensitization of those cells. IL-5 and IL-9 are responsible
for the activation and recruitment of eosinophils and
mast cells, while IL-13 induces goblet cell hyperplasia,
mucus hyper-secretion and airway hyper-responsiveness
[3, 4]. Nevertheless, the initiation of immune response is
believed to be triggered by the innate immune cells lo-
cated at the epithelium of the skin, lung, or gut. Injured
epithelial cells produce master regulatory cytokines, in-
cluding thymic stromal lymphopoietin (TSLP), IL-25
and IL-33. Subsequently, those cytokines stimulate Th2
cells and type 2 innate lymphoid cells (ILC2) to produce
Th2 cytokines. Furthermore, IL-33 and TSLP could dir-
ectly activate mast cells, while TSLP stimulates dendritic
cells to induce a Th2-like process.
In infection, Th2 immune response provides an effective
protection against helminths. Th2-induced IgE antibody
production, mucus secretion, and mast cell activation could
facilitate worm expulsion; while eosinophils recruited by
Th2 response directly kill larva [5]. Additionally, Th2
immune response is known to counteract Th1 response in
the microbicidal reactions, which could help limit the
tissue damage induced by Th1-mediated inflammation
[6]. Nevertheless, the polarization of immune responses
excessively toward Th2 immunity leads to atopic
disorders including asthma, allergic rhinitis, and atopic
dermatitis.
Studies have shown an important role of Th2 immun-
ity in the immunopathology of asthma, which could de-
termine the severity of the disease. This review will
describe the dysregulation of innate and adaptive type 2
immunity in severe asthma, the roles of the allergens
that are associated with severe asthma and targeting type
2 immune response in treatment of severe asthma.
Type 2-inflammation in the frame of unbalanced
adaptive immunity
Type 2-inflammation is traditionally sustained by Th2
cells and immunoglobulin E (IgE), as the main orches-
trators of type 2 adaptive immunity [7]. In atopic indi-
viduals, as a consequence of allergen exposure, dendritic
cells (DCs) acquire soluble protein allergen and reach
secondary draining lymph nodes, where antigens are
presented and naïve T cells polarize into either adaptive
Th2 cells or TFH cells. Through specific signalling path-
ways, Th2 cells move toward the site of inflammation
and produce Th2 cytokines, particularly IL-4, IL-5, IL-9,
and IL-13, which orchestrate and amplify type-2 re-
sponse [1, 7]. Tissue eosinophilia and mast cell hyperpla-
sia are independently regulated by IL-5 and IL-9, while
IL-13 is responsible for goblet cell proliferation as well
as mucin and mucus production, and airways
hyper-reactivity (AHR) [4, 8]. TFH cells are able to in-
duce IgE production by interacting with antigen-specific
B cells. Allergen-specific IgE crosslinking on basophils
and mast cells high-affinity Fcε receptor 1 (FcεR1) acti-
vates and releases through degranulation a number of
cytokines and mediators which further sustain type-2 re-
sponse [9, 10]. In fact, mast cells and basophils serve as
specified effectors in type 2 immunity response under
the influence of the type-2 cytokines environment in
local tissue [7]. Cytosolic granules in mast cells contain
cytokines (IL-4, IL-5, IL-6, and IL-13), biogenic amines
(histamine and serotonin), serglycin, proteoglycans, mast
cell-derived proteases (chymase and tryptase), and lipid
mediators (platelet-activating factor [PAF], leukotrienes,
prostaglandins, and sphingolipids). Recruitment of in-
flammatory cells, eosinophils in particular, smooth
muscle constriction, and increased vascular permeability
directly depend on mast cells mediators’ release [1, 11].
Basophils sustain the late phase of allergic response,
by promoting eosinophilic inflammation and mucus pro-
duction. In comparison with mast cells, ILC2s, and eo-
sinophils, they produce relatively high levels of IL-4,
thus acting as major Th2 differentiation promoters, in-
cluding ILC2 activation [12, 13].
Eosinophil activation is the key-step of type
2-inflammatory cascade, not only but mostly in the late
allergic response, and eosinophils exert a central role in
asthma pathogenesis through the release of four main
proteins retained in their cytoplasmic granules and a
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number of mediators [14]. Eosinophil cationic protein
(ECP) and eosinophil protein X (EPX), also called
eosinophil-derived neurotoxin (EDN), are mainly charac-
terized by cytotoxic properties and ribonuclease activity.
ECP also binds calcium-sensing receptor (CSR) on
smooth muscle cells. Eosinophil peroxidase (EPO) EPO
serves in catalysing the reaction of hydrogen peroxide
with halogens to hypohalides and, like the major basic
protein (MBP), promotes cytotoxic processes. MBP also
binds bronchial muscarinic M2 receptor [14].
Furthermore, eosinophils produce cytokines (mainly
IL-1b, IL-6, IL-8 and IL-4), lipid mediators and oxygen
radicals. Eosinophil activation results in dendritic cells
chemotactic activity, endothelial cells damaging, inhib-
ition of muscarinic receptors, altered repair processes
and induction of fibrosis, leading to airway hyperactivity
and wall remodelling [15, 16]. All of these effects have
direct implications in asthma control impairment and
exacerbations.
Recently, an increasing amount of evidence has dem-
onstrated that allergens can activate a Th2 response be-
side specific IgE involvement and that a number of other
environmental stimuli can trigger the same pattern of in-
flammation [17, 18]. In light of the emerging pathogenic
role of epithelial dysfunction and innate immunity, even
type 2-inflammation should be considered no more as a
consequence of allergenic stimuli only but the result of a
complex cross-talking between airway epithelium, innate
and adaptive immunity [19] (Fig. 1).
Type 2-inflammation in the frame of unbalanced
innate immunity
According to the most recent evidence, asthma pathogenesis
could be synthetically explained as the consequence of an
epithelial barrier dysfunction [17, 20] (Fig. 1), which is, after
all, the common background of allergic/type 2 respiratory
and skin diseases [21]. Epithelial barrier efficiency implies
two main aspects: anatomic integrity and functional, mainly
immunological, competence, the last aspect being strictly
connected with innate immunity [20]. Under the anatomic
perspective, the main problem with the epithelial barrier is
that asthmatics produce defective apical junctional com-
plexes (AJCs). Apical tight junctions and underlying adhe-
rens junctions [21] form AJCs, exerting a pivotal role in the
physical integrity and functional stability of airways mucosa.
Such a condition implies: an extremely weak physical
defence against environmental stimuli such as viruses,
allergens, and pollutants; and impaired epithelial wound re-
pair responses. This scenario is mainly due to genetic predis-
position, including primary genetic, secondary genetic (e.g.
somatic mutations), or epigenetic (e.g. altered miRNA, his-
tone acetylation/deacetylation, or DNA CpG methylation)
[20, 22]. A model known as epithelial-mesenchymal
transition (EMT) has been recently proposed as one of the
determinants of the epithelial barrier dysfunction and
epithelial-mesenchymal signalling dysregulation [17, 23]. A
loss of E-cadherin would explain the impaired differenti-
ation of epithelial cells into a mesenchymal phenotype, at
embryogenesis level. Although still controversial, it may ac-
count for impaired repair processes and airway remodelling
in asthmatics.
Smoke as well can be responsible for tight junctions
inefficiency [17, 24]. Data coming from in vitro studies
have confirmed that respiratory anatomic barrier impair-
ment is independent of the presence of inflammatory
cells or mediators, suggesting that epithelial injury plays
a causal role in the disease onset, not only as a conse-
quence of a longstanding inflammation [20, 25].
From a functional point of view, primary IFN produc-
tion deficiency in response to common respiratory vi-
ruses such as rhinovirus might be responsible for a kind
of aberrant differentiation of dendritic cells which
Fig. 1 Synthetic overview of asthma Th2 inflammation main determinants. EMT: epithelial-mesenchimal transition; AJC: apical junctional complexes
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become quite inefficient in anti-microbial protection
whilst activate pro-allergic pathways [26, 27]. In fact, the
lack of IFN β results in viral replication, cell cytotoxicity,
and mediator release associated with non-protective in-
flammation. Such a condition may account for the associ-
ation between frequent rhinovirus exposures in the lower
respiratory tract and multiple allergen sensitization early
in life [28, 29]. Also, a defective anti-oxidant pathway, in-
cluding superoxide dismutase and glutathione peroxidase
has been described in asthmatic subjects [30].
As a consequence of the impact of environmental
agents usually excluded from the exposure to the second
line immunity by the epithelial physical and functional
barrier, a number of impaired epithelial signalling path-
ways take place. The disordered response includes a Th2
oriented unbalanced inflammation, and an exaggerated
response to injury [31, 32]. The secretion of a number of
growth factors leads to altered tissue repair processes
and is responsible for airway remodelling, which further
sustains the epithelial physical inefficiency.
Mainly in response to selective toll-like receptor (TLR
4, 5 and 9 particularly) stimulation and to injury, the
epithelial cells, oriented by a network of transcription
factors including FoxA2 and Spdef, start producing key
cytokines such as chemokine (C-C motif ) ligand (CCL)
17 and CCL22 that exert most of Th2-type T-cell
chemotactic activity by interacting with the common
CCR4 receptor [21, 33]. Other master regulatory cyto-
kines produced by the epithelial cells include TSLP,
IL-25 and IL-33, as well as IL-13, TARC, RANTES,
eotaxins, and MCP-3 [21, 34, 35]. As a major effect,
those molecules interact with ILC2 to produce Th2 cyto-
kines and are able to control mucous cell differentiation.
Recently, an increasing amount of evidence supports the key
role of ILC2 in orchestrating a second-line adaptive type 2
immune response, a chronic eosinophilic airways inflamma-
tion in patients with asthma, particularly severe asthma, and
the consequent airways remodelling [7, 36, 37]. Further-
more, they seem involved in a kind of steroid resistance, es-
pecially under the influence of TSLP and IL-7 [34]. Besides
ILC2, epithelial-derived IL-33 and TSLP could directly acti-
vate mast cells and eosinophils, while TSLP stimulates den-
dritic cells to induce a Th2-like process [38, 39].
Emerging data suggest that mast cells, when directly
activated by plant-derived allergen proteases, further
promote IL-33 and release several cytokines, including
IL-2 and IL-4. This results in altered expansion of Treg
cells and dysregulated expression of their GATA3 and
Th2-type cytokines (IL-5, IL-13), which impairs their
regulatory and suppressive function towards Th2 inflam-
mation [7, 38].
Dendritic cells (DCs), mainly monocytic DCs, substan-
tially contribute to Th2 polarization even in the absence
of specific allergen stimulation [33, 40, 41]. Stimulation
of DCs pattern-recognition receptors, such as TLR, by
high dose of protease allergen results in production of
CCL17 and CCL22, which recruits effector Th2 cells to
produce IL-5 and IL-13 and further sustains eosinophilic
inflammation.
Allergen sensitization and type 2 immune
response: Beyond IgEs
Studies have shown that sensitization to several specific al-
lergens, including house dust mite (HDM), fungi, pollen,
animal dander, and cockroach, are associated with a more
severe phenotype of allergic asthma [42]. Allergen-derived
particles with a diameter ≤5 μm, such as HDM particles,
fungal spores, and animal dander, could penetrate deeply to
the lower airways, thereby more likely causing asthma [43].
HDM is one of the most common aeroallergens indu-
cing sensitization in 85% patients with asthma [44].
HDM can activate immune system by not only
mite-derived allergens (including proteases and other al-
lergenic determinants) but also components originated
from the environment (including LPS from bacteria,
β-glucan and chitin from fungi) [45]. HDM-derived al-
lergens can provoke a Th2 response leading to the pro-
duction of specific IgE antibody, eosinophil and mast
cell activation; while microbial contaminants in HDM
particles activate airway epithelial cells (AECs) via patho-
gen recognition receptor (PRR) and TLR to produce
TSLP, IL-25 and IL-33, which amplify type 2 immune re-
sponse induced by HDM [18, 45]. Nevertheless, HDM
can activate AECs to produce IL-6 and IL-8, leading to
an airway neutrophilia [46, 47]. In the airway epithelium
of severe asthmatic subjects, HDM could simulate the
proliferation of bronchial smooth muscle cells, which
could be abolished by montelukast [45]. Recently, HDM
was found to directly impair the airway epithelium by
causing oxidative damage, DNA double-strand break
and apoptosis in the AECs, which enhance the
HDM-induced airway inflammation in asthma [48, 49].
Consequently, HDM is one of the most powerful aller-
gens that could activate both innate and adaptive type 2
immune responses, thereby increasing asthma severity
in sensitized individuals. However, the underlying mech-
anism of HDM-induced airway inflammation and re-
modeling in asthma still remains to be investigated.
Sensitization to certain fungi has been associated with
increased asthma severity, mortality, hospitalization, and
intensive care admissions in adults [50]. There are 3 dis-
tinct ways of fungal allergen exposure associated with
severe asthma: 1) inhalation of spores or hyphae in the
airbone (e.g. Alternaria) that induce airway hyperrespon-
siveness in sensitized individuals; 2) colonization of fungi
(e.g. Aspergillus, Penicillium and Candida) in the air-
ways that produces a persistently allergenic stimulus; 3)
fungal colonization outside of the airways (e.g.
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dermatophyte infection of the skin or nails with Tricho-
phyton) that can trigger immediate hypersensitivity [51].
The fungal allergens can not only induce type 2-immune
response by their allergenic activity, but also trigger the
production of IL-6, and IL-8 from the AECs as well as
Th17 differentiation [52, 53], leading to a neutrophilic
inflammation of the airways. A wide spectrum of effects
of fungal allergens on the immune system enhances the
airway inflammation, leading to an increased asthma
severity.
There is abundant evidence showing the associations
of tree, grass, and weed pollen sensitization with severe
asthma [43]. The most relevant sources of allergenic
pollen worldwide include trees belonging to the Fagales,
Oleacea, and Cupressacecae families; grasses of the Pooi-
deae, Chloridoideae and Panicoideae families; weeds of
the Amaranthaceae, Asteraceae, and Urticaceae families
[54–56]. Recent findings showed that environmental
changes and air pollutants significantly enhance the al-
lergenic activity and biologic effects of the pollen on
type 2 immune response, which could increase the se-
verity of pollen-induced airway inflammation in asthma
[57]. Additionally, more evidence has implicated that
thunderstorm is a risk factor for severe asthma attacks in
sensitized subjects [58]. Consequently, an early warning
system for the outbreaks of thunderstorm asthma by ac-
companying meteorology and pollen counts has been
evaluated recently but has shown limited practical applica-
tions and needs to be optimized [58–60].
Other indoor allergens that are associated with in-
creased asthma risk include animal dander and cock-
roach. The presence of pets at home and sensitizations
to cat or dog allergens were also found to be associated
with severe asthma [61], while sensitization to cockroach
allergens was associated with more asthma symptoms
and more school missed due to asthma in children [62].
Nevertheless, the underlying mechanisms of how those
allergens enhance asthma risk and severity are not com-
pletely understood and need to be further investigated.
Although allergen sensitizations are well-known to be
associated with asthma, a number of studies reported a
lower frequency of allergen sensitizations, obtained by
skin prick tests (SPT) or specific serum IgE measure-
ment, in patients with severe asthma compared to those
with moderate or mild asthma [42, 63]. These findings
could be explained by a local allergen sensitization, lead-
ing to a production of specific IgE antibodies in the air-
ways, despite negative response in SPTs and low level of
serum specific IgE [64]. Additionally, T-lymphocyte acti-
vation and airway eosinophilia could exist in patients
with non-allergic asthma, suggesting that some factors
could induce a type 2-immune response without indu-
cing specific sensitizations [65, 66]. LPS-containing aller-
gens, such as HDM, could stimulate innate immune
cells to produce TSLP, IL-25 and IL-33, which could
provoke a type 2 immune response [1]. Proteases in al-
lergens are also able to activate proteinase-activated recep-
tor 2 (PAR2) expressed on AECs, inducing the production
of TSLP and IL-33 [53, 67]. Those cytokines could directly
activate ILC2 to produce a large amount of IL-5 and
IL-13, which cause an airway eosinophilia [68].
Taken together, allergens could induce type 2 im-
mune response in various ways to maintain and/or
amplify the airway inflammation and remodelling in
asthma, which is associated with severe asthma.
Understanding the mechanisms of allergen-induced
immune response help select a target therapy in man-
agement of severe asthma.
Type 2-immunity as a target of precision
treatments
The awareness of two different types of inflammation
(Th2-high and Th2-low), and that Th2 type is frequently
involved in several kinds of severe asthma, has driven re-
search to look for drugs targeting Th2 cytokines or their
production mechanisms [69, 70] (Table 1). Principal Th2
phenotype cells are eosinophils. Their differentiation,
maturation, and survival processes depend on several
cytokines, mainly interleukin-5 (IL-5), IL-3 and
granulocyte-macrophage colony-stimulating factor
(GM-CSF). Eosinophils, moreover, promote the syn-
thesis and release of IL-2, IL-3, IL-4, IL-5, IL-10,
IL-12, IL-13, IL-16, IL-25, transforming growth factor
(TGF) alpha and beta, CCL5, CCL11 and 13 [71, 72].
A GINA document [73] includes in therapeutic last
step two monoclonal antibodies for severe uncon-
trolled asthmatic patients. Omalizumab binds circulat-
ing IgEs in blood and interstitial space also reducing
basophils, mast cells and dendritic cells, [74, 75], re-
ducing inflammation prompted by mediators pro-
duced from mast cells and a decreased recruitment of
eosinophils in airways [75–78]. The efficacy of Omali-
zumab on symptoms [79], exacerbations rate [80], re-
duction of oral corticosteroids intake [81, 82], and
modulation of bronchial remodelling process [83], to-
gether with a good safety profile, both in adults and
children [84], has been clearly demonstrated. Real life
observations show comparable results with trials [82,
85–88] with significant improvement in FEV1 after
4 years of therapy with [89] and improvement in
quality of life (QoL) [90]. Mepolizumab, recently
added in the GINA guidelines is an anti-IL-5 human-
ized antibody [91]. Several studies demonstrate that
people with high levels of eosinophils and frequent
exacerbations better respond to this therapy. One of
the last trials demonstrated that mepolizumab pro-
vided a significant reduction of the exacerbations
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incidence rate in patients with blood mean eosino-
philia of 654 cells/μL and [92]. In a Cochrane
meta-analysis two studies reported a significant decrease in
the exacerbation rate in asthmatic patients with high level of
blood eosinophils (>300 μL). Four studies with serum eosin-
ophils heterogeneity levels have shown a non-significant dif-
ference between mepolizumab and placebo in terms of
reduction of exacerbations, probably due to the poor pheno-
typization of patients [93].
The main clinical trials assessing the efficacy of mepo-
lizumab [92, 94–98] reported a reduction of exacerba-
tions in treated patients, a good safety profile with
overall five deaths, three in active group [96], two in pla-
cebo [97, 98]. The most frequently adverse events (AEs)
were nasopharyngitis, upper respiratory tract infection
and headache, all with similar percentage both in active
and placebo group. MUSCA study evaluated the effect
on health related quality of life (HEQOL) with, a signifi-
cant change in favor of patients who had received mepo-
lizumab [92]. Recently approved by the Food and Drug
Aministration (FDA) in its intravenous formulation
(https://www.accessdata.fda.gov/drugsatfda_docs/applet-
ter/2016/761033orig1s000ltr.pdf ), reslizumab is an
IgG4/k humanized antibody targeting IL-5 [99]. Also,
reslizumab has exhibited a better efficacy in hypereosino-
philic severe asthmatic patients with at least 400 eosino-
phils/μL [100–102]. Regarding safety, two anaphylactic
reactions, responsive to standard treatment, a case of
pneumonia, one of worsening of asthma, upper respira-
tory tract infections, and nasopharyngitis, all in the resli-
zumab group, have been reported [100]. In addition, IL-5
receptor alpha has been targeted in the management of
severe asthma. Benralizumab is a biological drug targeting
IL-5Rα subunit [103], whose action is directed both on
eosinophils and on basophils [104]. A peculiarity of this
drug is its antibody-dependent cell-mediated cytotoxicity
(ADCC) effect [103], mediated by its action on NK cells
[105]. As well as mepolizumab and reslizumab, benralizu-
mab demonstrates a good efficacy and safety profile [106,
107]. In the CALIMA and SIROCCO trials significant re-
duction of exacerbations in people who assume drugs
compared with placebo both in 4 weeks administration
than in 8 weeks has been evidenced [108, 109]. The last
schedule is associated with a better efficacy in terms of re-
duction of exacerbations, asthma symptoms score and
lung function, according to the results shown by the regis-
trations trials, particularly CALIMA and SIROCCO. The
mechanisms underlying this trend are not yet completely
clear. The involvement of the ADCC pathway, which
probably entails a different timing in comparison with an
IL-blockage system, may account for it.
IL-4 and IL-13 have been analysed as well. IL-4 pathway
could be inhibited by either blocking IL-4 or the IL-4/IL-13
receptor. Pascolizumab, a humanized monoclonal antibody
(mAb) blocking IL-4, was found to be well tolerated; how-
ever, its effect on asthma symptoms and IgE level reduction
was insignificant [110]. A mutated IL-4 protein, pitrakinra,
acts as an antagonist binding to IL-4 receptor alpha chain,
thereby inhibiting both IL-4 and IL-13 pathway [111]. In a
clinical trial, inhaled pitrakinra could reduce significantly
asthma exacerbation and the effect was depedent on the
polymorphisms of IL-4Rα gene [111]. Dupilumab, another
monoclonal antibody to IL-4Rα, was effective in reducing
asthma exacerbation and several biomarkers, including
FeNO, eotaxin-3 as well as thymus and activation-regulated
cytokine (TARC) [112, 113]. IL-13 is as important as IL-4
in type 2 immune response in asthma. Anrukinzumab is a
humanized anti-IL-13 mAb, which has been tested in
Table 1 Biologicals targeting Th2 inflammation and their main effects
Drug Exacerbations Lung Function QoL
Mepolizumab (ANTI IL-5) Reduction [92, 94–96] Increase [92, 96]; no variation
in FEV1 [94, 96]
Increase [94, 97, 98], no variation
in QoL [96]
Reslizumab (ANTI IL-5) Reduction [100, 101] Increase of FEV1 [102] Increase of QoL [100]
Benralizumab (ANTI IL-5Ra) Reduction [103, 106–109] Increase of FEV1 [107–109];
no variation [106]
Increase of QoL [107–109];
no variation [106]
Pitrakinra (ANTI IL-4) Reduction in homozygous for the
rs8832 common G allele, rs1029489,
and the intronic SNPs rs3024585,
rs3024622 and rs4787956 [111]
Reduction [111] n.a.
Dupilumab (ANTI IL-4rα) Reduction [112, 113] Increase of FEV1 [112, 113] Increase of QoL [14, 112]
Lebrikizumab (ANTI IL-13) Reduction in high periostin group [115] Increase of FEV1 in high periostin
group [115, 116], response in high
periostin, IgE and eosinophils group,
[117], no variation [118]
No variation [115]
Tralokinumab (ANTI IL-13) Reduction in high-periostin and
high-DPP-4 groups [119]
Increase in high-periostin and
high-DPP-4 groups [119]
Increase of QoL [120]
Tezepelumab (ANTI TSLP) Reduction [122] Increase [122] Increase at medium and
high dosage [122]
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patients with asthma and ulcerative colitis in a phase II
study [114]. Lebrikizumab, a IgG4 humanized mAb, binds
to soluble IL-13 and block IL-13 pathway, was effective in
improving lung function and reducing asthma exacerbation
rates and FeNO levels in asthmatic patients with high
serum periostin level [115–118]. Tralokinumab, an IgG4
humanized mAb that binds to IL-13, showed a good toler-
ance and safety profile, and could improve quality of life.
However, no significant effect of tralokinumb on asthma
exacerbation rates was observed [119, 120]. In addition, tra-
lokinumab is currently being investigated in patients with
idiopathic pulmonary fibrosis due to the crucial role of
IL-13 in airway remodeling [121]. More recently stromal
lymphopoietin (TSLP), has been evaluated as pharmaceut-
ical target. Tezepelumab, has been evaluated in three differ-
ent dosage (70 or 210 every 4 weeks and 250 mg every 8)
administrated to asthmatic patients, with the aim to evalu-
ate the difference of exacerbations. The primary end point,
the annual exacerbations rate result significantly higher in
placebo (0.67) compared to treated patients (0.26; 0.19;
0.22) with a statistically significant reduction in who as-
sumed drug. Also lung function was found to be higher in
treated patients than placebo [122].
Conclusions
Th2 immunity exerts a pivotal role in asthma pathogen-
esis, beyond allergic sensitization. In fact, not only spe-
cific IgE in sensitized individuals but also many other
environmental stimuli, such as viruses and pollutants,
can trigger a Th2 response. Furthermore, a number of
allergens such as HDM and moulds are able to activate
both innate and adaptive type 2 immune reaction even
in the absence of specific IgE antibodies. An increasing
amount of evidence supports the relevance of airways,
particularly bronchial epithelium dysfunction, as the pre-
disposing condition of such impaired response. Epithelial
barrier efficiency implies two main aspects: anatomic in-
tegrity and functional, mainly immunological, compe-
tence, the last aspect being strictly connected with
innate immunity. Under this perspective the Th2
polarization is the result of a complex cross talking be-
tween airway epithelium, and innate and adaptive im-
munity. It entails major clinical implications in terms of
preventive and therapeutic options. Particularly, innate
response can be considered as a new target for innova-
tive selective treatments.
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